ProNAi reports positive PhII lymphoma results for DNAi drug using Marina's delivery tech

ProNAi Therapeutics, a licensee of RNAi specialist Marina Biotech ($MRNA), reported positive results from its so-called DNAi-based candidate PNT2258 for non-Hodgkin lymphoma. Using Marina's Smarticles delivery tech, the results from the Phase II trial shows meaningful therapeutic outcomes and a durable clinical response, according to the company. It is the first DNAi-based therapeutic being tested while RNAi is more commonly used to shut down genes. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…